The Company will provide a wide range of
adult-use brands and products to be sold at licensed retailers
across the province
LEAMINGTON, ON, June 29 2018 /CNW/ - Aphria Inc. ("Aphria"
or the "Company") (TSX: APH and US OTC: APHQF)
today announced that it has signed a Supply Agreement (the
"Agreement") with the Manitoba Liquor and Lotteries
Corporation ("MBLL") to provide a portfolio of high-quality,
branded cannabis and cannabis derivative products for sale in
Manitoba's adult-use market.
"We are thrilled to finalize this Agreement with the MBLL," said
Jakob Ripshtein, Chief Commercial Officer at Aphria. "Our broad
portfolio of adult-use brands and products has been specifically
developed to meet the needs of distinct consumer segments, whether
new to cannabis or long-time aficionados. We're excited that
Manitoba's adult consumers will
have the opportunity to discover our thoughtfully developed brands
and products."
Under the terms of the Agreement, the Company will supply up to
2.7 million grams of cannabis and cannabis derivative products in
the first year of the agreement, including both Ontario and BC dried flower, pre-rolls and
cannabis oils. The wide range of products will be available for
sale at licensed retailers across the province. It is anticipated
that additional products currently being developed by Aphria, such
as vapes and edibles, will also be made available in Manitoba when authorized for sale under the
Cannabis Act.
"This partnership with Manitoba
represents yet another significant step towards the future as we
continue to make history across Canada in the march towards legal sales this
fall" said Vic Neufeld, Chief
Executive Officer at Aphria. "With our annual production capacity
reaching 255,000 kg in early 2019 and our recently announced
partnership with Great North Distributors, we are incredibly
prepared to meet the anticipated demand in Manitoba and across Canada."
We Have a Good Thing Growing
About Aphria
Aphria is a leading global cannabis company driven by an
unrelenting commitment to our people, product quality and
innovation. Headquartered in Leamington,
Ontario – the greenhouse capital of Canada – Aphria has been setting the standard
for the low-cost production of safe, clean and pure
pharmaceutical-grade cannabis at scale, grown in the most natural
conditions possible. Focusing on untapped opportunities and backed
by the latest technologies, Aphria is committed to bringing
breakthrough innovation to the global cannabis market. The
Company's portfolio of brands is grounded in expertly-researched
consumer insights designed to meet the needs of every consumer
segment. Rooted in our founders' multi-generational expertise in
commercial agriculture, Aphria drives sustainable long-term
shareholder value through a diversified approach to innovation,
strategic partnerships and global expansion, with a presence in
more than 10 countries across 5 continents.
For more information, visit: aphria.ca
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to internal expectations,
estimated margins, expectations with respect to actual production
volumes, expectations of shipments to Provincial Liquor Control
Boards expectations for future growing capacity and costs, the
completion of any capital project or expansions, and expectations
with respect to future production costs. Forward-looking statements
necessarily involve known and unknown risks, including, without
limitation, risks associated with general economic conditions;
adverse industry events; marketing costs; loss of markets; future
legislative and regulatory developments involving medical
marijuana; inability to access sufficient capital from internal and
external sources, and/or inability to access sufficient capital on
favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory
matters; the ability of Aphria to implement its business
strategies; competition; crop failure; currency and interest rate
fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE Aphria Inc.